Top 3 Reasons Families Bank Cord Blood | ViaCord

ViaCord Family Cord Blood BankingFamilies choose to bank cord blood for various reasons – from family history of disease to peace of mind. We’ve put together our Top 3 list to help you with this important decision.

    1. The healing power of cord blood stem cells today. Cord blood stems cells are currently used in the treatment of nearly 80-diseases, including a wide range of cancers, blood disorders, and genetic diseases. Since the first cord blood transplant performed for a child with Fanconi’s anemia in 1988, over 30,000 cord blood transplants have been performed world-wide.1  Nearly half of all pediatric transplants worldwide now involve cord blood stem cells.2
    2. Immediate access to a related source of stem cells.  For medical treatments of non-genetic diseases that require a stem cell match, there is no better source than your child’s own cord blood stem cells. And if a donor is needed, a family member is always the first option a physician will look to for a match. Research shows transplant outcomes are better with related cord blood donor cells compared with unrelated cord blood or bone marrow donor cells.3
    3. Looking ahead to the future of cord blood stem cell medicine. Researchers around the globe are exploring new uses for cord blood. There are hundreds of studies taking place in an effort to increase therapeutic use of these amazing cells.  In fact two major clinical trials, one for cerebral palsy and another for type 1 diabetes, use the cord blood stem cells of the affected child in treatment. Participation in these studies is only possible because the child’s cord blood was saved with a family bank, like ViaCord.

Visit our Facebook page to hear from families like yours about their reasons for banking. And stop by our Family Stories page to meet some families that have used their banked cord blood in a medical treatment. It only takes one happy ending to understand why cord blood is so special.

 

 

References

1. Nature Biotechnology. Hemacord approval may foreshadow regulatory creep for HSC therapies.http://www.nature.com/nbt/journal/v30/n4/full/nbt0412-304.html. 4/10/12
2. National Marrow Donor Program®. Trends in allogeneic transplants: Figure 5, NMDP Transplants in Pediatric Patients by Cell Source (bone marrow, peripheral blood stem cells or cord blood), 1988-2010.http://www.marrow.org/PHYSICIAN/URD_Search_and_Tx/Number_of_Allogeneic_Tx_Perfor/index.html. Accessed 9/14/11
3. Gluckman E, Rocha V, Boyer-Chammard A, et al. For the Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337:373-381. Rocha V, Wagner JE, Sobocinski KA, et al. For the Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. Graft-vs-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med. 2000;342:1846-1854.

 

Leave a Reply

Your email address will not be published. Required fields are marked *